1
|
Torres A, Bassetti M, Welte T, Rivolo S, Remak E, Peral C, Charbonneau C, Hammond J, Ansari W, Grau S. Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain. J Med Econ 2020; 23:148-155. [PMID: 31686550 DOI: 10.1080/13696998.2019.1688819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Revised: 10/11/2019] [Accepted: 10/31/2019] [Indexed: 10/25/2022]
Abstract
Background: Adults admitted to hospital with community-acquired pneumonia (CAP) impose significant burden upon limited hospital resources. To achieve early response and possibly early discharge, thus reducing hospital expenditure, the choice of initial antibiotic therapy is pivotal.Methods: A cost-consequences model was developed to evaluate ceftaroline fosamil (CFT) as an alternative to other antibiotic therapies (ceftriaxone, co-amoxiclav, moxifloxacin, levofloxacin) for the empiric treatment of hospitalized adults with moderate/severe CAP (PORT score III-IV) from the perspective of the Spanish National Health System (NHS).Findings: Compared with ceftriaxone, the model predicted an increase in the number of CFT-treated patients discharged early (PDE) (30.6% vs. 26.1%) while decreasing initial antibiotic failures (3.8% vs. 7.6%). For patients with pneumococcal pneumonia, CFT was cost-saving vs. ceftriaxone (by 1.2%) and significantly increased PDE (32.1% vs. 24.6%). CFT resulted in cost-saving vs. levofloxacin, due lower initial antibiotic therapy costs and increased PDE (30.6% vs. 14.9%). Moxifloxacin and co-amoxiclav early response rate of 53.63% and 54.24% resulted in cost neutrality vs. CFT, with direct comparison hampered by the significantly different early response criteria utilized in the literature.Conclusions: Despite a higher unit cost, CFT is a reasonable alternative to other agents for adults hospitalized with moderate/severe CAP, given the projected higher PDE achieved with similar or lower total costs.
Collapse
Affiliation(s)
- Antoni Torres
- Hospital Clínic of Barcelona, Spain University of Barcelona, CIBERES, IDIBAPS, Barcelona, Spain
| | - Matteo Bassetti
- University of Udine and Santa Maria Misericordia University Hospital, Udine, Italy
- University of Genoa, Genoa, Italy
| | | | | | | | | | | | | | | | - Santiago Grau
- Hospital del Mar Universitat Autònoma de Barcelona, Barcelona, Spain
| |
Collapse
|
3
|
Jamal W, Abdulkareem H, Rotimi VO. Comparative in vitro activity of ceftaroline and comparator agents against nosocomial Gram-negative and Gram-positive clinically significant bacterial isolates from patients in a teaching hospital in Kuwait. J Chemother 2018; 30:213-223. [PMID: 29466931 DOI: 10.1080/1120009x.2018.1438768] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
The objective was to test the in vitro activities of ceftaroline and comparator agents against clinical isolates of Gram-negative and Gram-positive bacteria. Isolates were identified with VITEK II. Susceptibility testing was with E test. A total of 1264 isolates were tested. Compared to other cephalosporins, ceftaroline demonstrated excellent in vitro activities (MIC90, ≤0.5 mg/L) against Escherichia coli, Salmonella spp. and Haemophilus influenzae. When matched with the comparator cephalosporins, ceftaroline demonstrated the greatest activity against methicillin-susceptible Staphylococcus aureus (MSSA), with MIC90 of 0.25 mg/L. Ceftaroline's MIC90s against both community-associated methicillin-resistant S. aureus (MRSA) and hospital-acquired MRSA were 0.5 and 1 mg/L, respectively. Major discrepancies were noted between E test and disc diffusion tests for ceftaroline only against 16 Gram-negative and 16 Gram-positive isolates. Ceftaroline demonstrated an excellent in vitro activity against the majority of clinically significant Gram-negative and Gram-positive isolates obtained from proven cases of bacterial infections.
Collapse
Affiliation(s)
- Wafaa Jamal
- a Faculty of Medicine, Department of Microbiology , Kuwait University , Jabriya , Kuwait
- b Microbiology Unit, Mubarak Al Kabir Hospital , Jabriya , Kuwait
| | | | - Vincent O Rotimi
- a Faculty of Medicine, Department of Microbiology , Kuwait University , Jabriya , Kuwait
- b Microbiology Unit, Mubarak Al Kabir Hospital , Jabriya , Kuwait
| |
Collapse
|
5
|
Hodille E, Delouere L, Bouveyron C, Meugnier H, Bes M, Tristan A, Laurent F, Vandenesch F, Lina G, Dumitrescu O. In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections. Med Mal Infect 2016; 47:152-157. [PMID: 27856079 DOI: 10.1016/j.medmal.2016.10.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2016] [Accepted: 10/11/2016] [Indexed: 11/28/2022]
Abstract
OBJECTIVE We assessed the in vitro activity of ceftobiprole on 440 Staphylococcus aureus clinical strains isolated from bronchopulmonary infections (2010-2014). METHODS S. aureus isolates were characterized for methicillin resistance, PVL status, and clonal complex. All isolates were tested for minimal inhibitory concentrations (MIC) determination by broth microdilution method for ceftobiprole, ceftaroline fosamil, and comparator antibiotics (linezolid, tigecycline, vancomycin, and daptomycin). RESULTS A total of 325 (74%) strains were methicillin-susceptible S. aureus (MSSA) and 115 (26%) were methicillin-resistant S. aureus (MRSA); 105 (24%) S. aureus strains were PVL-positive, including 35.2% (37/105) MRSA and 64.8% (68/105) MSSA. Ceftobiprole was highly active against S. aureus with MIC90 of 1 mg/L, MICs ranging between 0.12 and 4mg/L (only one resistant strain, MIC of 4 mg/L). MIC50 and MIC90 were twice lower in MSSA than MRSA. Moreover, PVL+ MRSA were slightly more susceptible to ceftobiprole (MIC50 of 0.5 mg/L and MIC90 of 1 mg/L) than PVL- MRSA (MIC50 and MIC90 of 1 mg/L). The ceftobiprole-resistant strain was also resistant to ceftaroline fosamil and presented the D239L mutation in PBP2A. The comparator antibiotics were equally active on the strains tested, with MIC90 of 0.5 mg/L for ceftaroline fosamil, tigecycline, and daptomycin; 1 mg/L for vancomycin; and 2 mg/L for linezolid. CONCLUSIONS Our results suggest that ceftobiprole is highly active against S. aureus and is an effective alternative to vancomycin or linezolid in the management of staphylococcal pneumonia. However, close monitoring of isolates should be maintained to prevent resistant strain diffusion.
Collapse
Affiliation(s)
- E Hodille
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France; International Center for Infectiology Research, 69007 Lyon, France; CNRS UMR5308, Inserm U1111, École normale supérieure de Lyon, université Lyon 1, 69495 Lyon, France.
| | - L Delouere
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France
| | - C Bouveyron
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France
| | - H Meugnier
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France
| | - M Bes
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France; International Center for Infectiology Research, 69007 Lyon, France; CNRS UMR5308, Inserm U1111, École normale supérieure de Lyon, université Lyon 1, 69495 Lyon, France
| | - A Tristan
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France; International Center for Infectiology Research, 69007 Lyon, France; CNRS UMR5308, Inserm U1111, École normale supérieure de Lyon, université Lyon 1, 69495 Lyon, France
| | - F Laurent
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France; International Center for Infectiology Research, 69007 Lyon, France; CNRS UMR5308, Inserm U1111, École normale supérieure de Lyon, université Lyon 1, 69495 Lyon, France
| | - F Vandenesch
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France; International Center for Infectiology Research, 69007 Lyon, France; CNRS UMR5308, Inserm U1111, École normale supérieure de Lyon, université Lyon 1, 69495 Lyon, France
| | - G Lina
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France; International Center for Infectiology Research, 69007 Lyon, France; CNRS UMR5308, Inserm U1111, École normale supérieure de Lyon, université Lyon 1, 69495 Lyon, France
| | - O Dumitrescu
- Centre de référence des staphylocoques, institut des agents infectieux, hospices civils de Lyon, 69495 Lyon, France; International Center for Infectiology Research, 69007 Lyon, France; CNRS UMR5308, Inserm U1111, École normale supérieure de Lyon, université Lyon 1, 69495 Lyon, France
| |
Collapse
|
6
|
Abbott IJ, Jenney AWJ, Jeremiah CJ, Mirčeta M, Kandiah JP, Holt DC, Tong SYC, Spelman DW. Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia. Antimicrob Agents Chemother 2015; 59:7837-41. [PMID: 26392488 PMCID: PMC4649159 DOI: 10.1128/aac.02015-15] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2015] [Accepted: 09/12/2015] [Indexed: 01/13/2023] Open
Abstract
A total of 421 methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates were tested for ceftaroline susceptibility by Etest (bioMérieux). A multidrug resistant phenotype was found in 40.9%, and clonal complex 239 (CC239) was found in 33.5%. Ceftaroline nonsusceptibility (MIC, >1.0 μg/ml) was 16.9% overall. Nonsusceptibility was significantly higher in CC239 (41.1%, 58/141) and in isolates with a multidrug resistant phenotype (35.5%, 61/172) compared with comparators (P < 0.0001). Nonsusceptibility of common multidrug resistant MRSA clones limits the empirical use of ceftaroline for these infections.
Collapse
Affiliation(s)
- I J Abbott
- Alfred Hospital, Melbourne, Victoria, Australia
| | | | | | - M Mirčeta
- Alfred Hospital, Melbourne, Victoria, Australia
| | - J P Kandiah
- Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia
| | - D C Holt
- Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia
| | - S Y C Tong
- Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia
| | - D W Spelman
- Alfred Hospital, Melbourne, Victoria, Australia
| |
Collapse
|